United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

26 May 2017
Change (% chg)

-1.80kr (-1.32%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Sobi appoints Guido Oelkers as new CEO
Thursday, 4 May 2017 02:00am EDT 

May 4 (Reuters) - Swedish Orphan Biovitrum AB (Publ) :Guido Oelkers appointed President and CEO at Sobi.Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH.Says Oelkers has extensive experience from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro.  Full Article

Sobi Q1 EBITA SEK 406 mln, repeats outlook
Friday, 28 Apr 2017 02:00am EDT 

April 28 (Reuters) - Swedish Orphan Biovitrum :Q1 total revenue was SEK 1,396 mln (1,273).Says Q1 revenues grew 10 per cent overall, and by 47 percent adjusted for the one-time credit of SEK 322 million received in Q1 2016. .Q1 product revenue was SEK 1,269 mln (1,108).Q1 gross margin was 74 per cent (74).Q1 EBITA was SEK 406 mln (502).Says outlook for 2017 is unchanged.  Full Article

Sobi CEO sees broad interest in Partner Products platform
Thursday, 16 Feb 2017 02:27am EST 

Swedish Orphan Biovitrum AB CEO Geoffrey McDonough to reporters: says there is broad interest in the platform of the partner products division which sobi is considering selling . says his personal view is it would be premature to pay dividend for 2017 as company still in an active development phase Further company coverage: [SOBIV.ST] (Reporting By Anna Ringstrom) ((Anna.Ringstrom@thomsonreuters.com;)).  Full Article

Sobi Q4 EBITA lags expectations
Thursday, 16 Feb 2017 02:00am EST 

Swedish Orphan Biovitrum : Q4 ebita of sek 210 m (90) . Q4 total revenue of sek 1,292 m (814), an increase of 59 per cent (54 per cent at cer) . Q4 gross margin of 67 per cent (64) . Reuters poll: sobi q4 ebita was seen at sek 271 million, revenues at 1,278 million . says expects revenues for full year 2017 to be in range of sek 5,800 to 6,000 m . says 2017 gross margin is expected to be in range of 66 to 68 per cent .says expects ebita for full year to be in range of sek 1,600 to 1,700 m.  Full Article

Sobi confirms divestment discussions, shares halted
Friday, 3 Feb 2017 08:23am EST 

Swedish Orphan Biovitrum : Says confirms that company is in discussions with a private equity firm regarding a possible sale of its partner products business area excluding Kineret and Orfadin. . Says discussions may or may not lead to an agreement . "We have noted specific information in the market regarding a possible sale of Sobi Partner Products. We confirm that we are in discussions which may or may not lead to an agreement", said Geoffrey McDonough, CEO and President .Trade in the Sobi share was suspended at 13:16 GMT.  Full Article

Sobi's CEO divests a portion of shares
Monday, 8 Aug 2016 12:00pm EDT 

: Swedish Orphan Biovitrum (SOBI) says: . CEO Geoffrey McDonough has divested 300,000 of shares he holds in company. .The sale was made for personal financial reasons. After the transaction, McDonough will hold a total of 347,948 shares in the company..  Full Article

Sobi says to repurchase shares
Friday, 15 Jul 2016 02:30am EDT 

Swedish Orphan Biovitrum Publ AB (SOBI) : Says the board of directors exercises its authorisation for repurchase of shares to secure the company's commitments under the incentive programme . Says repurchase of the class C shares may be effected during the period 15 July - 27 September 2016 .Says the class C shares will, following the repurchase, be converted to common shares.  Full Article

SOBI Q2 EBITA above forecast
Friday, 15 Jul 2016 02:08am EDT 

Swedish Orphan Biovitrum : Q2 total revenue was sek 1,469 mln (764) . Q2 EBITA was sek 550 mln (74) . Q2 revenues include a sek 386 mln one-time credit from biogen triggered by first commercial sales of alprolix . Q2 gross margin was 72 per cent (63) . Outlook 2016 unchanged .Reuters poll: Sobi Q2 EBITA was seen at sek 435 mln, revenues at 1,317 mln.  Full Article

Pharming Group amends Ruconest distribution agreement with Sobi
Thursday, 14 Jul 2016 01:00am EDT 

Pharming Group NV : Pharming amends ruconest distribution agreement with Sobi . Pharming to directly commercialise Ruconest in 21 additional Western European, North African and Middle-Eastern markets .Pharming will expand current small European team of experienced hae marketing and medical affairs specialists.  Full Article

Sobi says CEO divests 230,000 shares
Monday, 16 May 2016 02:41am EDT 

Swedish Orphan Biovitrum (Sobi) : Says CEO Geoffrey McDonough has divested 230,000 of the shares he holds in the company . Says the sale was made in part to pay the estimated US tax due relating to the vesting of the company's 2013 long-term incentive programme, and to prepare to invest in the upcoming 2016 long-term incentive programme should it be approved by the Annual General Meeting later this month .  Full Article

More From Around the Web

BRIEF-Sobi appoints Guido Oelkers as new CEO

* Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH